董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Snehal Patel | 男 | Chief Executive Officer and Chief Financial Officer and Director | 62 | 600.13万美元 | 634.52 | 2026-05-26 |
| F. Joseph Daugherty | 男 | Chief Medical Officer and Director | 75 | 未披露 | 12.39 | 2026-05-26 |
| Eric Rothe | 男 | Director | 51 | 16.84万美元 | 38.26 | 2026-05-26 |
| Kenneth Hallock | 男 | Director | 77 | 16.84万美元 | 46.67 | 2026-05-26 |
| David McWilliams | 男 | Chairman of the Board and Director | 83 | 25.25万美元 | 72.43 | 2026-05-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Snehal Patel | 男 | Chief Executive Officer and Chief Financial Officer and Director | 62 | 600.13万美元 | 634.52 | 2026-05-26 |
| F. Joseph Daugherty | 男 | Chief Medical Officer and Director | 75 | 未披露 | 12.39 | 2026-05-26 |
| Jaye Thompson | 女 | Vice President Clinical & Regulatory Affairs | 60 | 未披露 | 未持股 | 2026-05-26 |
董事简历
中英对照 | 中文 | 英文- Snehal Patel
-
Snehal Patel自2016年6月起担任我们的首席执行官，自2010年2月起担任我们的首席财务官兼董事会成员。此外，自2009年以来，Patel先生曾在多家私营初创生物技术公司担任多个级别的顾问，经理和顾问，帮助开发癌症和其他治疗领域的临床和临床前资产。在2010年之前，Patel先生担任公共和私人公司的顾问，专注于干细胞治疗，多发性硬化T细胞治疗，溶瘤病毒和一次性生物技术制造设备。此外，Patel先生曾担任Sanders Morris Harris、Ferghana Partners和JP Morgan Chase的投资银行家，专注于梦百合和生物技术融资和战略交易。Patel先生还曾在拜耳公司（Bayer Corporation）以及设计和运营咨询公司从事运营和业务开发。Patel先生在麻省理工学院（Massachusetts Institute of Technology）获得化学工程理学士学位和生化工程理学硕士学位，并在芝加哥大学（University of Chicago）获得工商管理硕士学位。
Snehal Patel has over 30 years of experience in executive management, corporate development, operations, and investment banking in the healthcare industry. Mr. Patel has served as Greenwich Lifesciences, Inc.'s Chief Executive Officer since June 2016 and Greenwich Lifesciences, Inc.'s Chief Financial Officer and a member of Greenwich Lifesciences, Inc.'s board of directors since February 2010. In addition, since 2009, Mr. Patel has served as a consultant, manager, and advisor at various levels in multiple private start up biotech companies helping to develop clinical and pre clinical assets in cancer and other therapeutic areas. Prior to 2010, Mr. Patel served as a consultant to public and private companies focused on stem cell therapy, multiple sclerosis t cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment. In addition, Mr. Patel previously served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase focusing on healthcare and biotech financing and strategic transactions. Mr. Patel also previously worked in operations and business development at Bayer Corporation and in design and operations consulting firms. Mr. Patel received a Bachelor of Science degree in chemical engineering and a Master of Science degree in biochemical engineering from the Massachusetts Institute of Technology and a Masters of Business Administration degree from the University of Chicago. - Snehal Patel自2016年6月起担任我们的首席执行官，自2010年2月起担任我们的首席财务官兼董事会成员。此外，自2009年以来，Patel先生曾在多家私营初创生物技术公司担任多个级别的顾问，经理和顾问，帮助开发癌症和其他治疗领域的临床和临床前资产。在2010年之前，Patel先生担任公共和私人公司的顾问，专注于干细胞治疗，多发性硬化T细胞治疗，溶瘤病毒和一次性生物技术制造设备。此外，Patel先生曾担任Sanders Morris Harris、Ferghana Partners和JP Morgan Chase的投资银行家，专注于梦百合和生物技术融资和战略交易。Patel先生还曾在拜耳公司（Bayer Corporation）以及设计和运营咨询公司从事运营和业务开发。Patel先生在麻省理工学院（Massachusetts Institute of Technology）获得化学工程理学士学位和生化工程理学硕士学位，并在芝加哥大学（University of Chicago）获得工商管理硕士学位。
- Snehal Patel has over 30 years of experience in executive management, corporate development, operations, and investment banking in the healthcare industry. Mr. Patel has served as Greenwich Lifesciences, Inc.'s Chief Executive Officer since June 2016 and Greenwich Lifesciences, Inc.'s Chief Financial Officer and a member of Greenwich Lifesciences, Inc.'s board of directors since February 2010. In addition, since 2009, Mr. Patel has served as a consultant, manager, and advisor at various levels in multiple private start up biotech companies helping to develop clinical and pre clinical assets in cancer and other therapeutic areas. Prior to 2010, Mr. Patel served as a consultant to public and private companies focused on stem cell therapy, multiple sclerosis t cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment. In addition, Mr. Patel previously served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase focusing on healthcare and biotech financing and strategic transactions. Mr. Patel also previously worked in operations and business development at Bayer Corporation and in design and operations consulting firms. Mr. Patel received a Bachelor of Science degree in chemical engineering and a Master of Science degree in biochemical engineering from the Massachusetts Institute of Technology and a Masters of Business Administration degree from the University of Chicago.
- F. Joseph Daugherty
-
F.Joseph Daugherty自2019年9月起担任我们的首席医疗官，自2019年9月起担任董事会成员。此外，自2002年以来，Daugherty博士担任Phenolics，LLC和PharmaPrint，LLC的管理合伙人，PharmaPrint，LLC是从Phenolics，LLC分拆出来的，这两家公司都是营养公司。2002年至2018年，他首次担任Eleos Inc.的总裁，自2008年起担任Eleos Inc.的首席执行官，首席医疗官和董事会主席，Eleos Inc.是一家临床阶段的私人生物技术公司，专注于癌症反义技术。Daugherty博士还曾担任20多家公共和私人生物医学公司（包括杜邦公司）的管理顾问以及高级管理人员和董事。此外，Daugherty博士曾担任ConAgra&8217；s Biotech Division的总裁。Daugherty博士在华盛顿大学（Washington University）获得生物学文学学士学位，在内布拉斯加大学医学中心（University of Nebraska Medical Center）获得医学博士学位，在卡内基-梅隆大学泰珀分校（Carnegie-Mellon University Tepper）获得工业管理理学硕士学位。
F. Joseph Daugherty has over 35 years of experience in managing and overseeing biotechnology and biomedical projects. Dr. Daugherty has served as Greenwich Lifesciences, Inc.'s Chief Medical Officer since September 2019 and a member of Greenwich Lifesciences, Inc.'s board of directors since September 2019. In addition, since 2002, Dr. Daugherty has served as the Managing Partner of Phenolics, LLC and PharmaPrint, LLC which was spun off from Phenolics, LLC, both of which are nutraceutical companies. From 2002 until 2018, he served first as President, and since 2008 as Chief Executive Officer, Chief Medical Officer and the Chairman of the board of directors of Eleos Inc., a clinical stage private biotech company focused on anti sense technology in cancer. Dr. Daugherty also served in various other capacities as a management consultant as well as an officer and director to over 20 public and private biomedical companies including Dupont. In addition, Dr. Daugherty was President of ConAgra's biotech division. Dr. Daugherty received a Bachelor of Arts degree in biology from Washington University, a Doctor of Medicine degree from the University of Nebraska Medical Center and a Masters of Science in Industrial Administration from Carnegie Mellon University (Tepper). - F.Joseph Daugherty自2019年9月起担任我们的首席医疗官，自2019年9月起担任董事会成员。此外，自2002年以来，Daugherty博士担任Phenolics，LLC和PharmaPrint，LLC的管理合伙人，PharmaPrint，LLC是从Phenolics，LLC分拆出来的，这两家公司都是营养公司。2002年至2018年，他首次担任Eleos Inc.的总裁，自2008年起担任Eleos Inc.的首席执行官，首席医疗官和董事会主席，Eleos Inc.是一家临床阶段的私人生物技术公司，专注于癌症反义技术。Daugherty博士还曾担任20多家公共和私人生物医学公司（包括杜邦公司）的管理顾问以及高级管理人员和董事。此外，Daugherty博士曾担任ConAgra&8217；s Biotech Division的总裁。Daugherty博士在华盛顿大学（Washington University）获得生物学文学学士学位，在内布拉斯加大学医学中心（University of Nebraska Medical Center）获得医学博士学位，在卡内基-梅隆大学泰珀分校（Carnegie-Mellon University Tepper）获得工业管理理学硕士学位。
- F. Joseph Daugherty has over 35 years of experience in managing and overseeing biotechnology and biomedical projects. Dr. Daugherty has served as Greenwich Lifesciences, Inc.'s Chief Medical Officer since September 2019 and a member of Greenwich Lifesciences, Inc.'s board of directors since September 2019. In addition, since 2002, Dr. Daugherty has served as the Managing Partner of Phenolics, LLC and PharmaPrint, LLC which was spun off from Phenolics, LLC, both of which are nutraceutical companies. From 2002 until 2018, he served first as President, and since 2008 as Chief Executive Officer, Chief Medical Officer and the Chairman of the board of directors of Eleos Inc., a clinical stage private biotech company focused on anti sense technology in cancer. Dr. Daugherty also served in various other capacities as a management consultant as well as an officer and director to over 20 public and private biomedical companies including Dupont. In addition, Dr. Daugherty was President of ConAgra's biotech division. Dr. Daugherty received a Bachelor of Arts degree in biology from Washington University, a Doctor of Medicine degree from the University of Nebraska Medical Center and a Masters of Science in Industrial Administration from Carnegie Mellon University (Tepper).
- Eric Rothe
-
Eric Rothe之前从2006年10月到2010年2月担任公司总裁，从2007年10月到2010年2月担任公司首席执行官，从2006年10月到2009年2月担任公司董事会主席。此外，Rothe先生自2006年8月起担任公司董事会成员。自2017年8月以来，Rothe先生一直担任贝克休斯（Baker Hughes）的全球产品线负责人，这是一家能源技术公司。此前，从2014年9月到2017年7月被GE Oil&Gas收购贝克休斯（Baker Hughes），Rothe先生曾担任Mid-Continent和NE US Geomarket的Vice President，以及GE Oil&Gas的全球产品线负责人。Rothe从2012年到2014年担任National Oilwell Varco（世界上最大的油田设备供应商之一）国际销售和运营主管。在加入Oil&Gas部门之前，Rothe先生是U.T.M.D.Anderson Cancer Center的临床癌症遗传学项目总监，Introgen的项目经理，该公司是先进临床试验癌症产品的开发商，并为德克萨斯州的初创/小型生物技术公司提供咨询服务。Rothe先生在加州大学伯克利分校（University of California at Berkeley）获得分子与细胞生物学文学学士学位，并在莱斯大学（Rice University）获得工商管理硕士学位。
Eric Rothe is the founder of the Company and has over 12 years of industry and academic experience in gene based therapies and vaccines, including six years of laboratory experience. Mr. Rothe previously served as President of the Company from October 2006 to February 2010, Chief Executive Officer of the Company from October 2007 to February 2010 and Chairman of the Company's board of directors from October 2006 to February 2009. In addition, Mr. Rothe has served as a member of the Company's board of directors since August 2006. Since August 2017, Mr. Rothe has served as the Global Product Line Leader at Baker Hughes, an energy technology company. Previously, from September 2014 until its acquisition by GE Oil & Gas' acquisition of Baker Hughes in July 2017, Mr. Rothe served as Vice President of Mid Continent and NE US Geomarket and Global Product Line Leader of GE Oil & Gas. From 2012 to 2014, Mr. Rothe served as the International Sales and Operations Director at National Oilwell Varco, one of the world's largest oil field equipment providers. Before joining the oil & gas sector, Mr. Rothe was Director of the Clinical Cancer Genetics program at U.T. M.D. Anderson Cancer Center, Project Manager at Introgen, a developer of cancer products in advanced clinical trials, and provided consulting services for start up/small biotechnology companies in Texas. Mr. Rothe received a Bachelor of Arts degree in molecular and cell biology from the University of California at Berkeley and a Master of Business Administration degree from Rice University. - Eric Rothe之前从2006年10月到2010年2月担任公司总裁，从2007年10月到2010年2月担任公司首席执行官，从2006年10月到2009年2月担任公司董事会主席。此外，Rothe先生自2006年8月起担任公司董事会成员。自2017年8月以来，Rothe先生一直担任贝克休斯（Baker Hughes）的全球产品线负责人，这是一家能源技术公司。此前，从2014年9月到2017年7月被GE Oil&Gas收购贝克休斯（Baker Hughes），Rothe先生曾担任Mid-Continent和NE US Geomarket的Vice President，以及GE Oil&Gas的全球产品线负责人。Rothe从2012年到2014年担任National Oilwell Varco（世界上最大的油田设备供应商之一）国际销售和运营主管。在加入Oil&Gas部门之前，Rothe先生是U.T.M.D.Anderson Cancer Center的临床癌症遗传学项目总监，Introgen的项目经理，该公司是先进临床试验癌症产品的开发商，并为德克萨斯州的初创/小型生物技术公司提供咨询服务。Rothe先生在加州大学伯克利分校（University of California at Berkeley）获得分子与细胞生物学文学学士学位，并在莱斯大学（Rice University）获得工商管理硕士学位。
- Eric Rothe is the founder of the Company and has over 12 years of industry and academic experience in gene based therapies and vaccines, including six years of laboratory experience. Mr. Rothe previously served as President of the Company from October 2006 to February 2010, Chief Executive Officer of the Company from October 2007 to February 2010 and Chairman of the Company's board of directors from October 2006 to February 2009. In addition, Mr. Rothe has served as a member of the Company's board of directors since August 2006. Since August 2017, Mr. Rothe has served as the Global Product Line Leader at Baker Hughes, an energy technology company. Previously, from September 2014 until its acquisition by GE Oil & Gas' acquisition of Baker Hughes in July 2017, Mr. Rothe served as Vice President of Mid Continent and NE US Geomarket and Global Product Line Leader of GE Oil & Gas. From 2012 to 2014, Mr. Rothe served as the International Sales and Operations Director at National Oilwell Varco, one of the world's largest oil field equipment providers. Before joining the oil & gas sector, Mr. Rothe was Director of the Clinical Cancer Genetics program at U.T. M.D. Anderson Cancer Center, Project Manager at Introgen, a developer of cancer products in advanced clinical trials, and provided consulting services for start up/small biotechnology companies in Texas. Mr. Rothe received a Bachelor of Arts degree in molecular and cell biology from the University of California at Berkeley and a Master of Business Administration degree from Rice University.
- Kenneth Hallock
-
Kenneth Hallock自2019年9月起担任我们的董事会成员。Hallock先生目前是一家私营初创设备制造公司的高级经理和合伙人，并已担任该职位超过10年。此前，Hallock先生曾在NL Industries和Anderson Clayton等大型工业公司任职，这些公司随后被收购。Hallock先生在普林斯顿大学（Princeton University）获得化学工程工程学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Kenneth Hallock has over 40 years of experience in general management and new venture start ups and is a major investor in Greenwich Lifesciences, Inc.'s Company. Mr. Hallock has served as a member of Greenwich Lifesciences, Inc.'s board of directors since September 2019. Mr. Hallock is currently a senior manager and partner in a private start up equipment manufacturing company and has been in this role for over 10 years. Previously, Mr. Hallock worked in large industrial corporations such as NL Industries and Anderson Clayton, which were subsequently acquired. Mr. Hallock received a Bachelor of Engineering degree in chemical engineering from Princeton University and a Master of Business Administration degree from Harvard Business School. - Kenneth Hallock自2019年9月起担任我们的董事会成员。Hallock先生目前是一家私营初创设备制造公司的高级经理和合伙人，并已担任该职位超过10年。此前，Hallock先生曾在NL Industries和Anderson Clayton等大型工业公司任职，这些公司随后被收购。Hallock先生在普林斯顿大学（Princeton University）获得化学工程工程学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Kenneth Hallock has over 40 years of experience in general management and new venture start ups and is a major investor in Greenwich Lifesciences, Inc.'s Company. Mr. Hallock has served as a member of Greenwich Lifesciences, Inc.'s board of directors since September 2019. Mr. Hallock is currently a senior manager and partner in a private start up equipment manufacturing company and has been in this role for over 10 years. Previously, Mr. Hallock worked in large industrial corporations such as NL Industries and Anderson Clayton, which were subsequently acquired. Mr. Hallock received a Bachelor of Engineering degree in chemical engineering from Princeton University and a Master of Business Administration degree from Harvard Business School.
- David McWilliams
-
David McWilliams，他在建立生物制药和医疗保健公司方面拥有40多年的经验。此前，他曾担任BioHoton， Inc.的董事会主席，该公司是Hoton生命科学行业的倡导者。McWilliams先生曾担任多个私营生物技术公司的顾问和顾问，帮助开发癌症和其他治疗领域的临床前和临床资产。他还曾担任Opexa Therapeutics， Inc.（多发性硬化症细胞治疗公司）的首席执行官和董事会成员；担任细菌和真菌诊断公司Bacterial barcode， Inc.的首席执行官、总裁和董事会成员；担任癌症治疗公司Signase， Inc.的首席执行官和董事会成员；担任Encysive Pharmaceuticals， Inc.和Repros Therapeutics Inc.的首席执行官、总裁和董事会成员；担任Kallestad Diagnostics （Erbamont）的首席执行官兼总裁。McWilliams先生曾担任多种其他职务，包括Harleco Diagnostics Division （EM industries）的总裁、Abbott Laboratories的总经理和项目经理、McKinsey & Company的管理顾问。McWilliams先生此前是Greenwich LifeSciences的首席执行官。他获得Washington and Jefferson College的化学学士学位，以及Chicago大学的金融MBA学位。
David McWilliams has over 40 years of experience in building biopharmaceutical and healthcare companies. Mr. McWilliams has served as a member of Greenwich Lifesciences, Inc.'s board of directors since February 2009. He previously served as the Chief Executive Officer from February 2010 to June 2016 and Chairman of the board of directors of the Company since February 2009. In addition, since 2008, Mr. McWilliams has served as a consultant and an advisor at various levels in multiple private start up biotech companies to help develop clinical and pre clinical assets in cancer and other therapeutic areas. Mr. McWilliams previously served as the Chief Executive Officer and a member of the board of directors of Opexa Therapeutics, Inc., a multiple sclerosis cell therapy company, from 2004 until 2008. Mr. McWilliams also previously served as the Chief Executive Officer, President and a member of the board of directors of Bacterial Barcodes, Inc., a bacteria and fungi diagnostic company, and the Chief Executive Officer and a member of the board of directors of Signase, Inc., a cancer therapeutics company. Mr. McWilliams has also served in various other capacities including Chief Executive Officer, President and a member of the board of directors of both Encysive Pharmaceuticals, Inc. and Repros Therapeutics Inc.; Chief Executive Officer and President of Kallestad Diagnostics (Erbamont); President of Harleco Diagnostics Division (EM Industries); General Manager and Program Manager of Abbott Laboratories; and Management Consultant at McKinsey & Company. In addition to the foregoing, Mr. McWilliams currently serves as the Chairman of the board of directors of BioHouston, an advocate of the life sciences industry in Houston. Mr. McWilliams received a Bachelor of Arts degree in chemistry from Washington and Jefferson College and a Master of Business Administration degree from the University of Chicago. - David McWilliams，他在建立生物制药和医疗保健公司方面拥有40多年的经验。此前，他曾担任BioHoton， Inc.的董事会主席，该公司是Hoton生命科学行业的倡导者。McWilliams先生曾担任多个私营生物技术公司的顾问和顾问，帮助开发癌症和其他治疗领域的临床前和临床资产。他还曾担任Opexa Therapeutics， Inc.（多发性硬化症细胞治疗公司）的首席执行官和董事会成员；担任细菌和真菌诊断公司Bacterial barcode， Inc.的首席执行官、总裁和董事会成员；担任癌症治疗公司Signase， Inc.的首席执行官和董事会成员；担任Encysive Pharmaceuticals， Inc.和Repros Therapeutics Inc.的首席执行官、总裁和董事会成员；担任Kallestad Diagnostics （Erbamont）的首席执行官兼总裁。McWilliams先生曾担任多种其他职务，包括Harleco Diagnostics Division （EM industries）的总裁、Abbott Laboratories的总经理和项目经理、McKinsey & Company的管理顾问。McWilliams先生此前是Greenwich LifeSciences的首席执行官。他获得Washington and Jefferson College的化学学士学位，以及Chicago大学的金融MBA学位。
- David McWilliams has over 40 years of experience in building biopharmaceutical and healthcare companies. Mr. McWilliams has served as a member of Greenwich Lifesciences, Inc.'s board of directors since February 2009. He previously served as the Chief Executive Officer from February 2010 to June 2016 and Chairman of the board of directors of the Company since February 2009. In addition, since 2008, Mr. McWilliams has served as a consultant and an advisor at various levels in multiple private start up biotech companies to help develop clinical and pre clinical assets in cancer and other therapeutic areas. Mr. McWilliams previously served as the Chief Executive Officer and a member of the board of directors of Opexa Therapeutics, Inc., a multiple sclerosis cell therapy company, from 2004 until 2008. Mr. McWilliams also previously served as the Chief Executive Officer, President and a member of the board of directors of Bacterial Barcodes, Inc., a bacteria and fungi diagnostic company, and the Chief Executive Officer and a member of the board of directors of Signase, Inc., a cancer therapeutics company. Mr. McWilliams has also served in various other capacities including Chief Executive Officer, President and a member of the board of directors of both Encysive Pharmaceuticals, Inc. and Repros Therapeutics Inc.; Chief Executive Officer and President of Kallestad Diagnostics (Erbamont); President of Harleco Diagnostics Division (EM Industries); General Manager and Program Manager of Abbott Laboratories; and Management Consultant at McKinsey & Company. In addition to the foregoing, Mr. McWilliams currently serves as the Chairman of the board of directors of BioHouston, an advocate of the life sciences industry in Houston. Mr. McWilliams received a Bachelor of Arts degree in chemistry from Washington and Jefferson College and a Master of Business Administration degree from the University of Chicago.
高管简历
中英对照 | 中文 | 英文- Snehal Patel
Snehal Patel自2016年6月起担任我们的首席执行官，自2010年2月起担任我们的首席财务官兼董事会成员。此外，自2009年以来，Patel先生曾在多家私营初创生物技术公司担任多个级别的顾问，经理和顾问，帮助开发癌症和其他治疗领域的临床和临床前资产。在2010年之前，Patel先生担任公共和私人公司的顾问，专注于干细胞治疗，多发性硬化T细胞治疗，溶瘤病毒和一次性生物技术制造设备。此外，Patel先生曾担任Sanders Morris Harris、Ferghana Partners和JP Morgan Chase的投资银行家，专注于梦百合和生物技术融资和战略交易。Patel先生还曾在拜耳公司（Bayer Corporation）以及设计和运营咨询公司从事运营和业务开发。Patel先生在麻省理工学院（Massachusetts Institute of Technology）获得化学工程理学士学位和生化工程理学硕士学位，并在芝加哥大学（University of Chicago）获得工商管理硕士学位。
Snehal Patel has over 30 years of experience in executive management, corporate development, operations, and investment banking in the healthcare industry. Mr. Patel has served as Greenwich Lifesciences, Inc.'s Chief Executive Officer since June 2016 and Greenwich Lifesciences, Inc.'s Chief Financial Officer and a member of Greenwich Lifesciences, Inc.'s board of directors since February 2010. In addition, since 2009, Mr. Patel has served as a consultant, manager, and advisor at various levels in multiple private start up biotech companies helping to develop clinical and pre clinical assets in cancer and other therapeutic areas. Prior to 2010, Mr. Patel served as a consultant to public and private companies focused on stem cell therapy, multiple sclerosis t cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment. In addition, Mr. Patel previously served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase focusing on healthcare and biotech financing and strategic transactions. Mr. Patel also previously worked in operations and business development at Bayer Corporation and in design and operations consulting firms. Mr. Patel received a Bachelor of Science degree in chemical engineering and a Master of Science degree in biochemical engineering from the Massachusetts Institute of Technology and a Masters of Business Administration degree from the University of Chicago.- Snehal Patel自2016年6月起担任我们的首席执行官，自2010年2月起担任我们的首席财务官兼董事会成员。此外，自2009年以来，Patel先生曾在多家私营初创生物技术公司担任多个级别的顾问，经理和顾问，帮助开发癌症和其他治疗领域的临床和临床前资产。在2010年之前，Patel先生担任公共和私人公司的顾问，专注于干细胞治疗，多发性硬化T细胞治疗，溶瘤病毒和一次性生物技术制造设备。此外，Patel先生曾担任Sanders Morris Harris、Ferghana Partners和JP Morgan Chase的投资银行家，专注于梦百合和生物技术融资和战略交易。Patel先生还曾在拜耳公司（Bayer Corporation）以及设计和运营咨询公司从事运营和业务开发。Patel先生在麻省理工学院（Massachusetts Institute of Technology）获得化学工程理学士学位和生化工程理学硕士学位，并在芝加哥大学（University of Chicago）获得工商管理硕士学位。
- Snehal Patel has over 30 years of experience in executive management, corporate development, operations, and investment banking in the healthcare industry. Mr. Patel has served as Greenwich Lifesciences, Inc.'s Chief Executive Officer since June 2016 and Greenwich Lifesciences, Inc.'s Chief Financial Officer and a member of Greenwich Lifesciences, Inc.'s board of directors since February 2010. In addition, since 2009, Mr. Patel has served as a consultant, manager, and advisor at various levels in multiple private start up biotech companies helping to develop clinical and pre clinical assets in cancer and other therapeutic areas. Prior to 2010, Mr. Patel served as a consultant to public and private companies focused on stem cell therapy, multiple sclerosis t cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment. In addition, Mr. Patel previously served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase focusing on healthcare and biotech financing and strategic transactions. Mr. Patel also previously worked in operations and business development at Bayer Corporation and in design and operations consulting firms. Mr. Patel received a Bachelor of Science degree in chemical engineering and a Master of Science degree in biochemical engineering from the Massachusetts Institute of Technology and a Masters of Business Administration degree from the University of Chicago.
- F. Joseph Daugherty
F.Joseph Daugherty自2019年9月起担任我们的首席医疗官，自2019年9月起担任董事会成员。此外，自2002年以来，Daugherty博士担任Phenolics，LLC和PharmaPrint，LLC的管理合伙人，PharmaPrint，LLC是从Phenolics，LLC分拆出来的，这两家公司都是营养公司。2002年至2018年，他首次担任Eleos Inc.的总裁，自2008年起担任Eleos Inc.的首席执行官，首席医疗官和董事会主席，Eleos Inc.是一家临床阶段的私人生物技术公司，专注于癌症反义技术。Daugherty博士还曾担任20多家公共和私人生物医学公司（包括杜邦公司）的管理顾问以及高级管理人员和董事。此外，Daugherty博士曾担任ConAgra&8217；s Biotech Division的总裁。Daugherty博士在华盛顿大学（Washington University）获得生物学文学学士学位，在内布拉斯加大学医学中心（University of Nebraska Medical Center）获得医学博士学位，在卡内基-梅隆大学泰珀分校（Carnegie-Mellon University Tepper）获得工业管理理学硕士学位。
F. Joseph Daugherty has over 35 years of experience in managing and overseeing biotechnology and biomedical projects. Dr. Daugherty has served as Greenwich Lifesciences, Inc.'s Chief Medical Officer since September 2019 and a member of Greenwich Lifesciences, Inc.'s board of directors since September 2019. In addition, since 2002, Dr. Daugherty has served as the Managing Partner of Phenolics, LLC and PharmaPrint, LLC which was spun off from Phenolics, LLC, both of which are nutraceutical companies. From 2002 until 2018, he served first as President, and since 2008 as Chief Executive Officer, Chief Medical Officer and the Chairman of the board of directors of Eleos Inc., a clinical stage private biotech company focused on anti sense technology in cancer. Dr. Daugherty also served in various other capacities as a management consultant as well as an officer and director to over 20 public and private biomedical companies including Dupont. In addition, Dr. Daugherty was President of ConAgra's biotech division. Dr. Daugherty received a Bachelor of Arts degree in biology from Washington University, a Doctor of Medicine degree from the University of Nebraska Medical Center and a Masters of Science in Industrial Administration from Carnegie Mellon University (Tepper).- F.Joseph Daugherty自2019年9月起担任我们的首席医疗官，自2019年9月起担任董事会成员。此外，自2002年以来，Daugherty博士担任Phenolics，LLC和PharmaPrint，LLC的管理合伙人，PharmaPrint，LLC是从Phenolics，LLC分拆出来的，这两家公司都是营养公司。2002年至2018年，他首次担任Eleos Inc.的总裁，自2008年起担任Eleos Inc.的首席执行官，首席医疗官和董事会主席，Eleos Inc.是一家临床阶段的私人生物技术公司，专注于癌症反义技术。Daugherty博士还曾担任20多家公共和私人生物医学公司（包括杜邦公司）的管理顾问以及高级管理人员和董事。此外，Daugherty博士曾担任ConAgra&8217；s Biotech Division的总裁。Daugherty博士在华盛顿大学（Washington University）获得生物学文学学士学位，在内布拉斯加大学医学中心（University of Nebraska Medical Center）获得医学博士学位，在卡内基-梅隆大学泰珀分校（Carnegie-Mellon University Tepper）获得工业管理理学硕士学位。
- F. Joseph Daugherty has over 35 years of experience in managing and overseeing biotechnology and biomedical projects. Dr. Daugherty has served as Greenwich Lifesciences, Inc.'s Chief Medical Officer since September 2019 and a member of Greenwich Lifesciences, Inc.'s board of directors since September 2019. In addition, since 2002, Dr. Daugherty has served as the Managing Partner of Phenolics, LLC and PharmaPrint, LLC which was spun off from Phenolics, LLC, both of which are nutraceutical companies. From 2002 until 2018, he served first as President, and since 2008 as Chief Executive Officer, Chief Medical Officer and the Chairman of the board of directors of Eleos Inc., a clinical stage private biotech company focused on anti sense technology in cancer. Dr. Daugherty also served in various other capacities as a management consultant as well as an officer and director to over 20 public and private biomedical companies including Dupont. In addition, Dr. Daugherty was President of ConAgra's biotech division. Dr. Daugherty received a Bachelor of Arts degree in biology from Washington University, a Doctor of Medicine degree from the University of Nebraska Medical Center and a Masters of Science in Industrial Administration from Carnegie Mellon University (Tepper).
- Jaye Thompson
Jaye Thompson博士于2013年加入公司任临床和监察高级副总裁，此前自2009年起她任我公司董事。Thompson女士在临床研究行业有超过20年的工作经验，在加入我公司之前，她任Opexa Therapeutics, Inc.公司临床发展和法规事务部门高级副总裁。在加入Opexa公司之前，她曾任inVentiv Clinical Solutions, LLC公司法规事务和新兴生物科技部门高级副总裁，该公司是inVentiv Heatlh 公司（纳斯达克： VTIV）全资子公司，是一家全方位服务合同研究机构。在2006年该公司被inVentiv公司收购前，Thompson博士曾任SYNERGOS, Inc.公司总裁及创始人，该公司位于德克萨斯州伍德兰兹，是一家龙头合同研究机构。在她的领导下，SYNERGOS公司（创立于1991年）成长并在该地区成为最主要的临床研究机构。她在Applied Logic Associates开启她的职业生涯，任生物统计学家及项目负责人。Thompson博士拥有德州农工大学应用数学学士学位和休斯敦德克萨斯大学健康科学中心生物统计学硕士学位和博士学位。她现在海湾沿岸地区创新中心、商业执行委员会、MD Anderson技术审查委员会和BioHouston协会咨询委员会任职。
Jaye Thompson has over 30 years of experience in pharmaceutical and device product development. Dr. Thompson has served as Greenwich Lifesciences, Inc.'s Vice President Clinical & Regulatory Affairs since September 2019. Since December 2017, Dr. Thompson has served as a co founder and Chief Operating Officer of Proxima Clinical Research, Inc., a clinical research service provider. Dr. Thompson previously served as Senior Vice President of Clinical and Regulatory Affairs of Repros Therapeutics, a reproductive health company, from March 2013 to May 2017 and as a member of the board of directors of Repros Therapeutics from November 2009 to March 2013. Dr. Thompson previously served as Senior Vice President of Clinical Development and Regulatory Affairs of Opexa Therapeutics, a multiple sclerosis cell therapy company, from September 2009 to March 2013. In addition, Dr. Thompson has served at clinical stage biotech companies, in various senior clinical and regulatory roles and at inVentiv Clinical Solutions, a clinical research service provider. Dr. Thompson was the president and founder of SYNERGOS, Inc., a clinical research service provider, which was founded in 1991, and acquired by inVentiv Health, as a wholly owned subsidiary in 2006. Dr. Thompson has advised several of the region's leading life science companies on strategic and regulatory planning as well as clinical product development. She has directed and managed statistical analysis, data management, report writing, and the conduct of clinical trials for a wide variety of indications. Dr. Thompson has been actively involved in over 200 clinical trials for drugs, biologics and devices, and has been associated with numerous FDA regulatory submissions. Dr. Thompson has often represented sponsor companies at FDA meetings and advisory committee meetings, and she was appointed to the Governor's Texas Emerging Technology Fund Advisory Committee. Dr. Thompson received a BS in applied mathematics from Texas A&M University and an MS and a PhD in biostatistics from the University of Texas Health Science Center in Houston.- Jaye Thompson博士于2013年加入公司任临床和监察高级副总裁，此前自2009年起她任我公司董事。Thompson女士在临床研究行业有超过20年的工作经验，在加入我公司之前，她任Opexa Therapeutics, Inc.公司临床发展和法规事务部门高级副总裁。在加入Opexa公司之前，她曾任inVentiv Clinical Solutions, LLC公司法规事务和新兴生物科技部门高级副总裁，该公司是inVentiv Heatlh 公司（纳斯达克： VTIV）全资子公司，是一家全方位服务合同研究机构。在2006年该公司被inVentiv公司收购前，Thompson博士曾任SYNERGOS, Inc.公司总裁及创始人，该公司位于德克萨斯州伍德兰兹，是一家龙头合同研究机构。在她的领导下，SYNERGOS公司（创立于1991年）成长并在该地区成为最主要的临床研究机构。她在Applied Logic Associates开启她的职业生涯，任生物统计学家及项目负责人。Thompson博士拥有德州农工大学应用数学学士学位和休斯敦德克萨斯大学健康科学中心生物统计学硕士学位和博士学位。她现在海湾沿岸地区创新中心、商业执行委员会、MD Anderson技术审查委员会和BioHouston协会咨询委员会任职。
- Jaye Thompson has over 30 years of experience in pharmaceutical and device product development. Dr. Thompson has served as Greenwich Lifesciences, Inc.'s Vice President Clinical & Regulatory Affairs since September 2019. Since December 2017, Dr. Thompson has served as a co founder and Chief Operating Officer of Proxima Clinical Research, Inc., a clinical research service provider. Dr. Thompson previously served as Senior Vice President of Clinical and Regulatory Affairs of Repros Therapeutics, a reproductive health company, from March 2013 to May 2017 and as a member of the board of directors of Repros Therapeutics from November 2009 to March 2013. Dr. Thompson previously served as Senior Vice President of Clinical Development and Regulatory Affairs of Opexa Therapeutics, a multiple sclerosis cell therapy company, from September 2009 to March 2013. In addition, Dr. Thompson has served at clinical stage biotech companies, in various senior clinical and regulatory roles and at inVentiv Clinical Solutions, a clinical research service provider. Dr. Thompson was the president and founder of SYNERGOS, Inc., a clinical research service provider, which was founded in 1991, and acquired by inVentiv Health, as a wholly owned subsidiary in 2006. Dr. Thompson has advised several of the region's leading life science companies on strategic and regulatory planning as well as clinical product development. She has directed and managed statistical analysis, data management, report writing, and the conduct of clinical trials for a wide variety of indications. Dr. Thompson has been actively involved in over 200 clinical trials for drugs, biologics and devices, and has been associated with numerous FDA regulatory submissions. Dr. Thompson has often represented sponsor companies at FDA meetings and advisory committee meetings, and she was appointed to the Governor's Texas Emerging Technology Fund Advisory Committee. Dr. Thompson received a BS in applied mathematics from Texas A&M University and an MS and a PhD in biostatistics from the University of Texas Health Science Center in Houston.